Eli Lilly (LLY)
(Delayed Data from NYSE)
$762.66 USD
+8.49 (1.13%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $762.65 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$762.66 USD
+8.49 (1.13%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $762.65 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Zacks News
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
by Kinjel Shah
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Amazon (AMZN) Boosts Pharmacy Efforts With Lilly's Partnership
by Zacks Equity Research
Amazon (AMZN) teams up with Lilly to deliver drug prescriptions that are sent to the latter's direct-to-consumer service, LillyDirect.
Lilly (LLY) Partners Amazon to Deliver Drugs Like Zepbound
by Zacks Equity Research
Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.
Eli Lilly (LLY) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Eli Lilly (LLY) reachead $757.84 at the closing of the latest trading day, reflecting a +0.38% change compared to its last close.
The Zacks Analyst Blog Highlights Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly
by Zacks Equity Research
Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly are part of the Zacks top Analyst Blog.
Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk
by Zacks Equity Research
Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.
Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab
by Zacks Equity Research
The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.
S&P 500 Soars to New Highs: 5 Best Stocks YTD
by Sweta Killa
The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.
Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study
by Zacks Equity Research
Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Viking (VKTX) Stock Down on Novo Nordisk's Obesity Pill Data
by Zacks Equity Research
Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Zacks Market Edge Highlights: NVDA, DELL, LLY, CMG and CAVA
by Zacks Equity Research
NVDA, DELL, LLY, CMG and CAVA have been highlighted in this Market Edge article.
Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Buy Red-Hot Stocks Now or Wait?
by Tracey Ryniec
After a mesmerizing rally to start 2024, is it too late to buy the hottest stocks?
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
by Zacks Equity Research
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
Eli Lilly (LLY) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $792.28, marking a +1.3% move from the previous day.
The Zacks Analyst Blog Highlights Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic
by Zacks Equity Research
Eli Lilly, The Procter & Gamble, Morgan Stanley, AT&T and Medtronic are part of the Zacks top Analyst Blog.
Top Analyst Reports for Eli Lilly, Procter & Gamble & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), The Procter & Gamble Company (PG) and Morgan Stanley (MS).
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Market Edge Highlights: AAPL, COST, WSM, LLY and HLT
by Zacks Equity Research
AAPL, COST, WSM, LLY and HLT have been highlighted in this Market Edge article.
How to Start Stock Investing in Your 50s
by Tracey Ryniec
Think you're too old to start buying stocks? Think again. Here's some tips.
5 Best-Performing S&P 500 Stocks Halfway Through Q1
by Sweta Killa
Nvidia (NVDA), Eli Lilly (LLY), Meta Platforms (META), Uber Technologies (UBER) and Ralph Lauren (RL) are the five best-performing stocks in the S&P 500.